Composition, additive, and method for producing composition
The combination of cyclodextrin and NMN stabilizes NMN against heat and water, addressing its instability and enabling its use in food, beverages, and pharmaceuticals.
Patent Information
- Application Number
- JP2023075892
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-01
- Publication Date
- 2024-11-14
AI Technical Summary
Nicotinamide mononucleotide (NMN) is unstable and decomposes easily under heat and water, making it unsuitable for heat sterilization processes in food and beverages.
A composition containing cyclodextrin (CyD) and nicotinamide mononucleotide is developed to stabilize NMN, with specific ratios and methods for mixing and optional inclusion of derivatives and salts.
The composition effectively stabilizes NMN against heat and prolonged storage, maintaining its integrity for use in various products.
Smart Images

Figure 2024160656000001 
Figure 2024160656000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition, an additive, and a method for making the composition. [Background technology]
[0002] In recent years, various studies have shown that taking nicotinamide mononucleotide (hereinafter sometimes referred to as "NMN") can improve degenerative changes caused by aging. For this reason, NMN has been attracting attention as an additive ingredient in food and beverages, medicines, cosmetics, etc.
[0003] For example, Patent Document 1 discloses a dietary supplement that contains NMN as an active ingredient. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2018-002604 A Summary of the Invention [Problem to be solved by the invention]
[0005] However, NMN is an unstable substance that is easily decomposed by heat and water. Since it decomposes in a short time, it cannot withstand the heat sterilization process after being added to food and beverages, and it is difficult to withstand the addition of water. It will break down.
[0006] Therefore, an object of the present invention is to provide a composition, an additive, and a method for producing the composition that can stabilize NMN. [Means for solving the problem]
[0007] To achieve the above object, the composition of the present invention contains cyclodextrin (hereinafter sometimes referred to as "CyD") and nicotinamide mononucleotide.
[0008] The additive of the present invention is an additive added to nicotinamide mononucleotide and includes cyclodextrin.
[0009] The method for producing the composition of the present invention includes a mixing step of mixing cyclodextrin and nicotinamide mononucleotide. Effect of the Invention
[0010] According to the present invention, NMN can be stabilized. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following description in any way.
[0012] [1. Composition] First, the composition of the present invention will be described. As described above, the composition of the present invention contains cyclodextrin and nicotinamide mononucleotide.
[0013] The CyD may be, for example, one containing at least one of α-CyD, β-CyD, γ-CyD, δ-CyD, ε-CyD, ζ-CyD, η-CyD, and θ-CyD. From the viewpoint of availability, it is preferable to contain at least one of α-CyD, β-CyD, and γ-CyD, and from the viewpoint of solubility in water, it is more preferable to contain α-CyD. The CyD may also be a derivative of the CyD or a salt thereof.
[0014] The CyD derivative is not particularly limited, and examples thereof include alkylated derivatives, hydroxyalkylated derivatives, alkoxyalkylated derivatives, acetylated derivatives, quaternary ammonium salt derivatives, carboxyalkylated derivatives, maltosylated derivatives, and glucosylated derivatives.
[0015] The salt of CyD is not particularly limited, and examples thereof include acid addition salts and base addition salts. Examples of the acid addition salts include salts having an ion of an inorganic acid or an organic acid. Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of the organic acid include acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acid, aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butylacetic acid, trimethylacetic acid, etc. Examples of the base addition salt include salts having an ion of an inorganic base or an organic base. Examples of the inorganic base include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, calcium hydroxide, etc. Examples of the organic base include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.
[0016] The CyD may be prepared by any method. For example, a purified CyD artificially synthesized by a method of producing CyD from amylopectin of starch through a reaction with cyclodextrin glycosyltransferase may be used. The cyclodextrin glycosyltransferase may be produced, for example, by culturing a microorganism that produces the cyclodextrin glycosyltransferase in a culture solution and extracting the cyclodextrin glycosyltransferase from the culture solution. Examples of the microorganism that produces the cyclodextrin glycosyltransferase include bacteria of the genus Bacillus. Examples of the starch that can be used include potato, corn, waxy corn, and wheat. Commercially available purified CyD may also be used.
[0017] The NMN may be, for example, at least one of α-NMN and β-NMN, and preferably contains β-NMN. The NMN may also be a derivative of NMN or a salt thereof.
[0018] The NMN derivative is not particularly limited, and may be, for example, pharma- ceutical acceptable. In the present invention, "pharma-ceutical acceptable" refers to not causing any adverse reaction, such as an allergic reaction, when administered to an animal.
[0019] The salt of NMN is not particularly limited, and examples thereof include acid addition salts and base addition salts. Examples of the acid addition salts include salts having an ion of an inorganic acid or an organic acid. Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of the organic acid include acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acid, aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butylacetic acid, trimethylacetic acid, etc. Examples of the base addition salt include salts having an ion of an inorganic base or an organic base. Examples of the inorganic base include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, calcium hydroxide, etc. Examples of the organic base include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.
[0020] The NMN may be prepared by any method. For example, NMN that has been artificially synthesized by chemical synthesis, enzymatic methods, fermentation, or the like and then purified may be used. In addition, since NMN is a component that is widely present in living organisms, NMN obtained by extraction and purification from natural raw materials such as animals, plants, and microorganisms may also be used. Commercially available purified NMN may also be used.
[0021] The composition of the present invention may be, for example, a solid composition or a liquid composition. The term "solid composition" refers to a composition that is solid at room temperature. The term "liquid composition" refers to a composition that is liquid at room temperature.
[0022] The composition of the present invention may be, for example, a beverage, a food, a supplement, a general food, a health food, a food for special uses, an animal feed, a medicine, or a quasi-drug.
[0023] Although there is no administrative definition of the supplement in Japan, it is, for example, a product in the form of a tablet or capsule in which a specific ingredient is condensed, and examples of the product include beverages, food, general foods, health functional foods, foods for special uses, etc. The supplement may include, for example, those defined as dietary supplements in the United States and those defined as food supplements in Europe.
[0024] The general foods are, for example, those defined by the standards for nutritional ingredient labeling in the food labeling system related to nutrition and health functions, and are so-called health foods. Examples of the general foods include nutritional supplements, dietary supplements, and nutritionally adjusted foods.
[0025] Examples of the health functional foods include functional foods, nutrient functional foods, and foods for specified health uses, which are defined by the standards for nutritional component labeling in the food labeling system regarding nutrition and health functions.
[0026] Examples of the special dietary foods include foods for specified health uses, foods for the sick, powdered milk for pregnant women and nursing mothers, infant formula, foods for people with difficulty swallowing, etc., as defined by the standards for nutritional composition labeling in the food labeling system for nutrition and health functions.
[0027] When the composition of the present invention is provided as the beverage, food, supplement, general food, health functional food, or special purpose food, it may be in the form of, for example, tablets, capsules, powders, granules, drinks (including solutions and suspensions), etc. It may also be provided for consumption in a state of being mixed with various foods and beverages, for example, in the form of soft drinks, tea drinks, seasonings, processed foods, desserts, confectioneries (e.g., gums, candies, jellies), dairy products (e.g., yogurt, lactic acid bacteria drinks, etc.).
[0028] When the composition of the present invention is provided as animal feed, for example, it may be ingested by animals as is, or may be mixed with other solid feed or drinking water and then ingested by animals.
[0029] When the composition of the present invention is provided as a drug or quasi-drug, it may be, for example, an oral preparation that is orally ingested, an external preparation that is applied to a target site, or an injectable preparation that is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, etc.
[0030] When the pharmaceutical or quasi-drug of the composition of the present invention is an oral preparation, its form may be, for example, powder, granule, tablet, liquid, gel, paste, capsule such as hard capsule or soft capsule, caplet, tablet, gel, jelly, gummy, wafer, biscuit, cookie, cake, chewable, syrup, stick, etc. The daily intake amount per body weight is not particularly limited, and can be appropriately set depending on the mode of use and the contents of use of the user. The intake amount per one time per body weight is also not particularly limited. When the pharmaceutical is an oral preparation, it may be taken, for example, before a meal, between meals, after a meal, or simultaneously with a meal.
[0031] When the pharmaceutical or quasi-drug of the composition of the present invention is an external preparation, its form may be, for example, lotion, milky lotion, gel, cream, ointment, powder, granule, etc. Specific examples include lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, body shampoo, face wash, soap, foundation, face powder, lipstick, lip gloss, blush, eye shadow, hair styling agent, hair growth agent, aqueous ointment, oily ointment, eye drops, eye wash, poultice, gel, etc. The amount of use is not particularly limited, and can be appropriately selected in consideration of various factors such as the age, weight, constitution, and application site of the subject individual. The frequency of application to the subject is not particularly limited.
[0032] When the pharmaceutical or quasi-drug that is the composition of the present invention is an injection, it may be, for example, an aqueous suspension or oil suspension that can be prepared using a dispersing agent, a wetting agent, or / and a suspending agent. The injection may be in the form of a solution or suspension prepared using a solvent or diluent. As the solvent, for example, sterile water, Ringer's solution, or isotonic saline solution is used. The injection may be a powder that is reconstituted using an appropriate solution. The injection may contain, for example, a stabilizer, a pH regulator, or / and a surfactant as other components. The injection may be provided, for example, in the form of a unit dose ampoule or a multi-dose container. The dosage of the injection may be appropriately determined depending on, for example, its type and form, the age, sex, weight, and severity of symptoms of the subject. In addition, the injection may be administered once or in several doses per day within the desired dosage range, and may be administered before, between, after, or simultaneously with a meal.
[0033] The composition of the present invention may contain other components. The other components may be selected arbitrarily depending on the application. Examples of the other components include solvents such as water and organic solvents, excipients, binders, gloss agents, lubricants, stabilizers, thickeners, emulsifiers, antioxidants, pH adjusters, colorants, flavors, sweeteners, acidulants, and / or additives.
[0034] Examples of the water include purified water, hot water, ion-exchanged water, etc. The water may be tap water or the like that has been subjected to a specific treatment, and examples of the specific treatment include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, etc.
[0035] The organic solvent may be at least one selected from the group consisting of alcohols (e.g., methanol, ethanol, propanol, etc.), esters (e.g., methyl acetate, ethyl acetate, etc.), alkanes (e.g., pentane, hexane, heptane, etc.), and halogenated alkanes (e.g., chloromethane, chloroethane, chloroform, or methylene chloride, etc.).
[0036] The excipient may be, for example, at least one selected from the group consisting of lactose hydrate, crystalline cellulose, corn starch, mannitol, and potato starch.
[0037] The binder may be, for example, at least one selected from the group consisting of microcrystalline cellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, povidone, low-substituted hydroxypropyl cellulose, and corn starch.
[0038] The polishing agent may be, for example, at least one selected from the group consisting of shellac, paraffin wax, and beeswax.
[0039] The lubricant may be, for example, at least one selected from the group consisting of magnesium stearate, talc, calcium stearate, stearic acid, sodium lauryl sulfate, and carnauba wax.
[0040] The stabilizer and thickener may be, for example, at least one selected from the group consisting of carrageenan, sodium carboxymethylcellulose, xanthan gum, guar gum, and pectin.
[0041] The emulsifier may be, for example, at least one selected from the group consisting of glycerin fatty acid esters, saponin, sucrose fatty acid esters, and lecithin.
[0042] The antioxidant may be, for example, at least one selected from the group consisting of L-ascorbic acid, erythorbic acid, catechin, dibutylhydroxytoluene, tocopherol, and butylhydroxyanisole.
[0043] The pH adjuster may be, for example, at least one selected from the group consisting of baking soda, sodium bicarbonate, citric acid, lactic acid, and calcined alum.
[0044] The coloring agent may be, for example, at least one selected from the group consisting of annatto color, turmeric color, caramel color, carotene color, gardenia color, carminic acid color, edible tar color, copper chlorophyll, monascus color, and safflower color.
[0045] The flavoring may be, for example, a chemically synthesized flavoring or a flavoring derived from a natural product. The flavoring may be a mixture of the chemically synthesized flavoring and the flavoring derived from a natural product.
[0046] The sweetener may be, for example, at least one selected from the group consisting of aspartame, acesulfame potassium, licorice extract, xylitol, saccharin, stevia, and D-sorbitol.
[0047] The acidulant may be, for example, at least one selected from the group consisting of citric acid, L-tartaric acid, and lactic acid.
[0048] Examples of the additives include food additives, pharmaceutical additives, and additives for quasi-drugs other than those listed as the other components.
[0049] The compositions of the present invention may be used, for example, in humans or non-human animals, such as mammals, including cows, pigs, horses, sheep, goats, donkeys, monkeys, dogs, cats, rabbits, mice, rats, hamsters, and guinea pigs.
[0050] The weight ratio (C / N) of the weight of the CyD (C) to the weight of the NMN (N) contained in the composition of the present invention is not particularly limited and can be set as appropriate, and is, for example, 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and is, for example, 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0051] [2. Additives] Next, the additive of the present invention will be described. As described above, the additive of the present invention is an additive to be added to nicotinamide mononucleotide, and contains cyclodextrin.
[0052] The NMN may be the same as the NMN described in the composition of the present invention. The CyD may be the same as the CyD described in the composition of the present invention.
[0053] The additive of the present invention is, for example, a stabilizer for the NMN. The stabilization by the stabilizer refers to, for example, stabilization against heat treatment, medium- to long-term storage, and the like. The heat treatment temperature is, for example, 40 to 200°C, 60 to 150°C, or 80 to 100°C, and the heat treatment time is, for example, 1 to 180 minutes, 15 to 120 minutes, or 30 to 60 minutes. The medium- to long-term storage temperature is, for example, 20 to 85°C, 25 to 70°C, or 35 to 50°C, and the storage period is, for example, 3 hours to 2 months, 1 day to 1 month, or 3 days to 2 weeks.
[0054] The additive of the present invention may contain other components. The other components may be, for example, the same as the other components described above in the composition of the present invention.
[0055] The additive of the present invention may be added in any amount relative to the weight (N) of the NMN. For example, the weight ratio (C / N) of the weight (C) of the CyD to the weight (N) of the NMN may be 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and may be added so that, for example, it is 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0056] [3. Method for producing the composition] Next, the method for producing the composition of the present invention will be described. As described above, the method for producing the composition of the present invention includes a mixing step of mixing cyclodextrin and nicotinamide mononucleotide. The method for producing the composition of the present invention further includes, for example, a mixing step of mixing water.
[0057] The NMN may be, for example, the same as the NMN described in the composition of the present invention. The CyD may be, for example, the same as the CyD described in the composition of the present invention. Furthermore, the water may be, for example, the same as the water described in the composition of the present invention.
[0058] The mixing step may be performed by hand or by a mixing device, which may be a commonly used mixing means such as a mixer or a propeller agitator.
[0059] The method for producing the composition of the present invention may further include a drying step. Examples of the drying step include hot air drying, reduced pressure drying, freeze drying, and natural drying.
[0060] In the method for producing a composition of the present invention, the weight ratio (C / N) of the weight of the CyD (C) to the weight of the NMN (N) is, for example, 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and may be, for example, 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0061] When the mixing step includes a step of mixing the water, the ratio ([C+N] / W) of the total ([C+N]) of the weight of CyD (C) and the weight of NMN (N) to the weight of water (W) is not particularly limited and can be set appropriately, for example, 0.001 or more, 0.005 or more, 0.01 or more, 0.05 or more, 0.1 or more, 0.5 or more, 1 or more, 2 or more, 3 or more, 4 or more, or 4.5 or more, and for example, 2000 or less, 1500 or less, 1200 or less, 1100 or less, 1000 or less, 500 or less, 200 or less, 100 or less, 50 or less, 20 or less, 10 or less, 6 or less, or 5 or less. In addition, in calculating the ratio, for example, when the volume of the water is 1 mL, the weight of the water (W) can be calculated assuming that it is 1 g. EXAMPLES
[0062] Next, the present invention will be described in more detail, but the present invention is not limited to the following examples.
[0063] In this embodiment, the residual rate of NMN was determined using HPLC as described below, but the method for determining the residual rate is not limited to this. For example, the residual rate may be determined using a device or method capable of quantitative analysis such as a mass spectrometer, a spectrophotometer, an X-ray analyzer, or an elemental analyzer.
[0064] In the following examples and comparative examples, the residual rate of NMN after heat treatment was calculated by the following method.
[0065] (Method of calculating the residual rate of NMN after heat treatment) The NMN solution described below and a composition containing NMN and CyD (hereinafter simply referred to as the "NMN / CyD composition") were analyzed using a high performance liquid chromatograph (hereinafter referred to as "HPLC") before and after heat treatment. The remaining rate of NMN after heat treatment was calculated from the peak area of the obtained chromatogram and the following formula (1). Residual rate of NMN after heat treatment (%) = (peak area after heat treatment / peak area before heat treatment) x 100 (1)
[0066] (1) Stability of NMN after heat treatment at high temperatures [Example 1] A mixture of β-NMN and α-CyD in a weight ratio (C / N) of 2.95 was mixed with purified water in a ratio ([C+N] / W) of 4.9375, and the mixture was dried under reduced pressure at room temperature for 24 hours. The resulting NMN / CyD composition was dissolved in 10 mL of purified water and analyzed by HPLC. In addition, a mixture of β-NMN and α-CyD in a weight ratio (C / N) of 2.95 was mixed with purified water in a ratio ([C+N] / W) of 4.9375, and the mixture was dried under reduced pressure at room temperature for 24 hours. The resulting NMN / CyD composition was dissolved in 10 mL of purified water and analyzed by HPLC under the same conditions as before the heat treatment. The results are shown in Table 1.
[0067] [Comparative Example 1] An "NMN solution" prepared by dissolving 66 mg of β-NMN in 10 mL of purified water was analyzed by HPLC. Furthermore, the NMN solution was heat-treated at 96°C for 30 minutes and then analyzed by HPLC. The HPLC analysis conditions were the same as those in Example 1. The results are shown in Table 1.
[0068] [Table 1]
[0069] As shown in Table 1, the NMN / CyD composition (NMN + CyD) had a higher residual rate than the NMN solution (NMN alone). This shows that the composition containing NMN and CyD has improved stability in a high temperature environment.
[0070] (2) Stability of NMN during medium- to long-term storage [Example 2] The NMN / CyD composition prepared under the same conditions as in Example 1 was analyzed by HPLC. In addition, the NMN / CyD composition was also analyzed by HPLC after storage at 40°C for one week under the same conditions as before storage. The results are shown in Table 2.
[0071] [Comparative Example 2] An NMN solution prepared under the same conditions as Comparative Example 1 was analyzed by HPLC. In addition, the NMN solution was also analyzed by HPLC after storage at 40°C for one week. The HPLC analysis conditions were the same as those in Example 2. The results are shown in Table 2.
[0072] [Table 2]
[0073] As shown in Table 2, the residual rate of NMN in the presence of CyD was higher than that of NMN alone. This indicates that the composition containing NMN and CyD has improved stability during medium- to long-term storage.
[0074] <Additional Notes> Some or all of the above embodiments may be described as follows, but are not limited to the following supplementary notes. (Appendix 1) A composition comprising a cyclodextrin and nicotinamide mononucleotide. (Appendix 2) 2. The composition of claim 1, wherein the nicotinamide mononucleotide comprises β-nicotinamide mononucleotide. (Appendix 3) 3. The composition of claim 1 or 2, wherein the cyclodextrin comprises an α-cyclodextrin. (Appendix 4) 4. The composition of any one of claims 1 to 3, wherein the composition is a liquid composition. (Appendix 5) The composition of any one of claims 1 to 4, wherein the composition is a beverage. (Appendix 6) An additive to be added to nicotinamide mononucleotide, the additive comprising cyclodextrin. (Appendix 7) The additive of claim 6, wherein the additive is a nicotinamide mononucleotide stabilizer. (Appendix 8) mixing cyclodextrin and nicotinamide mononucleotide; A method for producing a composition according to any one of claims 1 to 5. [Industrial Applicability]
[0075] As described above, according to the present invention, NMN can be stabilized.
Claims
1. A composition comprising a cyclodextrin and nicotinamide mononucleotide.
2. 2. The composition of claim 1, wherein the nicotinamide mononucleotide comprises β-nicotinamide mononucleotide.
3. The composition of claim 1 , wherein the cyclodextrin comprises α-cyclodextrin.
4. The composition of claim 1 , wherein the composition is a liquid composition.
5. The composition of claim 1 , wherein the composition is a beverage.
6. An additive to be added to nicotinamide mononucleotide, the additive comprising cyclodextrin.
7. The additive of claim 6 , wherein the additive is a nicotinamide mononucleotide stabilizer.
8. mixing cyclodextrin and nicotinamide mononucleotide; A method for producing the composition according to any one of claims 1 to 5.
Citation Information
Patent Citations
Natural killer cell activators
JP2018002604A
